<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Allogeneic hematopoietic stem cell transplantation is the only potentially curative therapeutic option for many malignant and <z:e sem="disease" ids="C1518374" disease_type="Disease or Syndrome" abbrv="">nonmalignant hematologic disorders</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Despite this, several factors unfavorably affect the outcome of this procedure and in particular <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (cGVHD) remains the principal cause of morbidity after allogeneic transplantation </plain></SENT>
<SENT sid="2" pm="."><plain>Here we present our experience regarding a patient affected by extensive <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD (cGVHD) treated only with extracorporeal photopheresis procedure (ECP) as first line treatment </plain></SENT>
<SENT sid="3" pm="."><plain>The patient, presenting an high risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), underwent an allogeneic peripheral stem cells transplantation </plain></SENT>
<SENT sid="4" pm="."><plain>About 2months after transplantation she experienced a hematological and clinical relapse of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>After reinduction therapy with <z:chebi fb="0" ids="2038">azacitidine</z:chebi> she obtained a second complete remission </plain></SENT>
<SENT sid="6" pm="."><plain>Because of the risk of relapse related to a strong <z:chebi fb="1" ids="35705">immunosuppressant</z:chebi> therapy and the previous infectious complication, we decided to start a treatment with ECP alone for cGVHD </plain></SENT>
<SENT sid="7" pm="."><plain>After six procedure the patient obtained a complete resolution of <z:hpo ids='HP_0000001'>all</z:hpo> signs and symptoms of the cGVHD </plain></SENT>
<SENT sid="8" pm="."><plain>This experience may support the possibility to use only an immunomodulant treatment like ECP for the cGVHD, reducing the risk of complications of prolonged <z:chebi fb="1" ids="35705">immunosuppressant</z:chebi> treatment </plain></SENT>
</text></document>